Equity Investment

University of Birmingham spinout ChromaTwist nabs 487K pounds to develop fluorescent dyes for flow cytometry

This firm said that this second round of equity investment will allow it to continue product development with industry partners and enable market entry next year.

November 14, 2022

QuantuMDx, Sansure ink agreement for MDx POC system, tests

Sansure Biotech is an in vitro diagnostic test provider based in Hunan, China.

September 5, 2022

SD Biosensor, SJL Partners to acquire Meridian Bioscience

Under the terms of the agreement, shareholders of Cincinnati, OH-based Meridian Bioscience will receive $34 per share in cash, which represents a premium of 16% compared to the firm's one-month average price per share starting Thursday.

July 6, 2022

Cancer mortality declined by 27% over past five decades

Mortality rates decreased "significantly" for 12 of the 15 top cancer sites analyzed, according to a team led by Tyler Kratzer from the American Cancer Society. The researchers also found greater mortality declines for certain cancers in particular years, such as lung cancer being 44% lower in 2019 compared with its peak rate in 1993.

November 11, 2021

10 rules for better lab meetings -- and better science

The rules focus on issues of diversity, equity, and inclusion, and they are intended to help science professionals make deliberate investments in long-term practices that cultivate a rich, productive lab environment.

May 31, 2021

Bio-Rad's Q2 revenue drops

Sales dropped 6.2% to $536.9 million compared with $572.6 million for the second quarter of 2019. In particular, revenues in the company's clinical diagnostics segment decreased by 20.7%.

July 30, 2020

Canopy snaps up German cytometry firm Zellkraftwerk

Zellkraftwerk, which is based in Leipzig, Germany, has a platform of workflow solutions for cytometry. Among other things, the company markets the ZellScanner device, which enables the analysis of cells using Zellkraftwerk's ChipCytometry technology.

April 28, 2019

Pathology AI developer PathAI raises $60M

The Boston company said it plans to use the funding to improve its flagship pathology research platform, fund R&D for new tools and medical devices, and enhance its offerings to existing partners. PathAI has been signing partnerships with pharmaceutical companies to accelerate drug development, as well as with diagnostic laboratories to support pathologists in bringing faster and more accurate diagnostics to patients.

April 21, 2019

Page 1 of 1